-
Press Release
Novartis receives approval for first malaria medicine for newborn babies and young infants
-
Press Release
Duplicate ROOT Novartis and Medicines for Malaria Venture announce positive efficacy and safety data for a novel treatment for babies <5 kg with malaria
-
Press Release
Novartis and Medicines for Malaria Venture announce decision to move to Phase 3 study for novel ganaplacide/lumefantrine-SDF combination in adults and children with malaria
-
Press Release
Novartis renews commitment to neglected tropical disease and malaria elimination, investing USD 250 million over five years to research and develop new treatments
-
Story
Staying one step ahead of the malaria parasite -
Story
Tackling the health toll of climate change -
Press Release
Novartis and Medicines for Malaria Venture report positive results for Phase 2b study of novel ganaplacide/lumefantrine combination in children with malaria
-
Press Release
Novartis reaches milestone delivery of 1 billion courses of antimalarial treatment
-
Story
Ensuring medicine supply to patients during COVID-19 -
Press Release
International research partnership and EDCTP to invest €44m in next-generation antimalarials to combat drug-resistant malaria in Africa
-
Story
Asian health experts call for final push to wipe out deadliest form of malaria -
Story
African experts call for renewed global drive to beat malaria